In a trial published recently in the New England Journal of Medicine (NEJM), evolocumab, a monoclonal antibody that inhibits circulating PCSK9 (proprotein convertase subtilisin-kexin type 9) by preventing it from binding to the low-density lipoprotein (LDL) receptor, was found to reduce LDL cholesterol and cardiovascular risk in patients with elevated cholesterol despite high-intensity statin therapy.
Slomski A. Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol. JAMA. 2017;317(20):2054. doi:10.1001/jama.2017.5656
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: